Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive ...

Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based ...
Yahoo Finance

Mabwell Initiates Phase III Clinical Study of its Nectin-4-Targeting ADC 9MW2821 for the Treatment of Triple-Negative Breast Cancer

SHANGHAI, April 23, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announces the initiation of a Phase III clinical ...
Fierce Biotech

Gilead pays $3.1B upfront for Tubulis to bolster oncology ADC pipeline

Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...
Targeted Oncology

FDA Grants Fast Track Designation to ADC for Platinum-Resistant Ovarian Cancer

Fast Track status enables closer FDA engagement to potentially accelerate development of a CDH6-directed ADC in ...